The Irish Contract Research Organisation (CRO) Ulysses Neuroscience today announced that it has successfully raised €500K in investment from Enterprise Ireland and private investment company Growing Capital.
Since its foundation in June 2019, Ulysses Neuroscience has been providing the patient community and the global pharmaceutical industry with ground-breaking research services to advance knowledge and therapies for psychiatric diseases and rare neurological disorders. Ulysses Neurosciences’ recent strategic move to the newly built Pioneer Group life sciences facilities in Cherrywood in Dublin has initiated a transformative phase of growth for the company, opening doors to a new industry network. The company is currently hiring for preclinical and clinical neuroscience positions in the psychedelic, psychiatric and rare neurodevelopmental research space.
Dr. Massimiliano Bianchi, CEO of Ulysses Neuroscience said, “This raise of €500,000 in investment is an important milestone allowing us to expand our patient-centric and translational neuroscience research platforms. With a portfolio of globally based pharma clients and an annual revenue of over €1 million, we have been able to break through the CRO market and are helping a range of industries to bring their new therapies into clinical trials and subsequently onto the market.”
Dr Massimiliano Bianchi added, “The relocation to the Pioneer Group facilities in Cherrywood was driven by our vision to be the vanguard CRO in neuroscience drug discovery. Our new laboratories are fully operational and dedicated to performing and progressing the company biomarker and cell cultures operations.”
Gianni Matera, Founder, Growing Capital said, “We are delighted to support Ulysses Neuroscience in their pursuit to combat psychiatric diseases and rare neurological disorders, contributing to advancements in the pharmaceutical industry. We’ve been truly impressed by Ulysses’ commitment to actively engaging patients in the research and drug development journey, ensuring their voices are not only heard but valued at every stage. It’s gratifying to see this approach being acknowledged by the global pharmaceutical industry.”
Leo Clancy, CEO, Enterprise Ireland said, “Enterprise Ireland is delighted to support Ulysses Neuroscience and the important work they are doing in bringing ground-breaking treatment in the field of neurodevelopment to the market for the benefit of the patient community right across the world. With this funding the company plans to scale its operations, and continue to expand its market reach across the US, EU and Asian markets with a particular focus on expanding its clinical biomarker services. We look forward to working with the Ulysses Neuroscience team to realise their global ambition.”
(Source: Enterprise Ireland)
